One‐year experience in patients treated with auranofin following completion of a parallel, controlled trial comparing auranofin, gold sodium thiomalate, and placebo

Open Access
Publisher Website
Google Scholar
Abstract
Following a 21‐week double‐blind trial that compared the effects of treatment with auranofin (AUR), gold sodium thiomalate, and placebo in 193 patients, 147 patients entered a 1‐year, open‐label study of treatment with AUR (6 mg/day). Results of this open‐label study suggest that AUR has a long‐term use profile similar to that of other slow‐acting antirheumatic drugs. AUR appears to be capable of sustaining an initial response to gold sodium thiomalate. The withdrawal rate remains relatively high: Nearly half of the study patients had discontinued AUR by the end of 1 year.